Published in Vaccine Weekly, May 3rd, 2006
Study 1: According to recently published research from the United States, Chlamydia trachomatis protection is conferred by mucosal immunization with recombinant major outer membrane protein (MOMP) genetically linked with modified cholera toxin.
"Chlamydia trachomatis is a major human health pathogen due to its role in sexually transmitted diseases. Thus, there is a need to develop an effective vaccine at the mucosal surface against this pathogen.
"In an effort to develop a mucosal vaccine, a modified cholera toxin gene was genetically linked to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-05-03)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.